Author:
Rebecca Vito W.,Somasundaram Rajasekharan,Herlyn Meenhard
Abstract
AbstractMetastatic melanoma is challenging to manage. Although targeted- and immune therapies have extended survival, most patients experience therapy resistance. The adaptability of melanoma cells in nutrient- and therapeutically-challenged environments distinguishes melanoma as an ideal model for investigating therapy resistance. In this review, we discuss the current available repertoire of melanoma models including two- and three-dimensional tissue cultures, organoids, genetically engineered mice and patient-derived xenograft. In particular, we highlight how each system recapitulates different features of melanoma adaptability and can be used to better understand melanoma development, progression and therapy resistance.
Funder
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
U.S. Department of Defense
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry
Reference98 articles.
1. Schmidberger, H. et al. Long-term survival of patients after ipilimumab and hypofractionated brain radiotherapy for brain metastases of malignant melanoma: sequence matters. Strahlentherapie und Onkol. 194, 1144–1151 (2018).
2. Arheden, A. et al. Real-world data on PD-1 inhibitor therapy in metastatic melanoma. Acta Oncologica 58, 962–988 (2019).
3. Fischer, G. M. et al. Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases. Cancer Discov. 9, 628–645 (2019).
4. Cramer, S. F. The origin of epidermal melanocytes. Implications for the histogenesis of nevi and melanomas. Arch. Pathol. Lab. Med. 115, 115–119 (1991).
5. Chang, D. Z. et al. Clinical significance of BRAF mutations in metastatic melanoma. J. Transl. Med. 2, 46 (2004).
Cited by
131 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献